Concord Medical Reports Third Quarter 2014 Financial Results Reiterates FY14 Financial Forecast BEIJING

Concord Medical Reports Third Quarter 2014 Financial Results

Reiterates FY14 Financial Forecast

BEIJING, November 17, 2014 Concord Medical Services Holdings Limited ( Concord Medical or the Company ) (NYSE: CCM), an

operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the third quarter ended September 30, 2014[1].

Third Quarter 2014 Highlights

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, stated: The past quarter was

marked by our excellent operational and financial performances. Our top and bottom lines increased by 13.6% and 30.3%, respectively, over the period of the previous year, and the growth rate is also higher. We are seeing more contribution from our

network centers, especially from the centers which provide high-end radiotherapy and diagnostic services to our patients, such as CyberKnife and PET-CT centers. It is our corporate strategy to provide the best treatment and services available to our

patients. The strategy is paying off and we will continue to pursue the strategy, as we build Concord into a leading operator of cancer specialty hospitals and radiotherapy and diagnostic centers in China.

During the quarter, we have achieved a great milestone in our corporate strategy. Datong Meizhong Jiahe Cancer Center has received the relevant

government approvals. It is the first free-standing cancer specialty hospital in the Concord network. We plan to replicate the model in other cities in China, especially in cities we have existing centers in operation. Thus, we can take advantage of

the medical and operational teams in place. The Datong Meizhong Jiahe Cancer Center is expected to open in the first half of 2015. Our business development team is actively exploring similar opportunities in other cities in China.

Currently, the healthcare reform in China is progressing quickly. The reform is touching upon many historically challenging issues, such as

multi-location practice for doctors and equipment licensing to private hospitals. We are very pleased to see that the new government initiatives have brought great feasibility and visibility to our strategic plans. As doctors enjoy more freedom of

practice, similar to their foreign counterparts, we will be able to attract more talents to our future hospitals, providing Concord Medical with a strong advantage, as our hospitals will be operated and managed similar to the model of best hospitals

Giving the solid operational and financial performance in the first three quarters of the year, we

reiterate our full year guidance forecast.

Third Quarter 2014 Results by Segment

The total number of centers in

operation was 141 in 56 cities around China as of September 30, 2014, same as the previous quarter. At the end of this quarter the Company entered into agreements to establish two additional centers.

Net revenues from the network business were RMB143.2 million ($23.3 million) for the third quarter of 2014, representing an increase of 9.2% from RMB131.1

million for the third quarter of 2013, primarily due to the increased contribution from PET-CT and CyberKnife centers.

Gross profit margin of the network

business was 50.7% for the third quarter of 2014, as compared with 56.0% for the third quarter of 2013. The lower gross profit margin was primarily due to higher medical consumable expenses during the quarter.

Capital expenditure of the network business was RMB16.7 million ($2.7 million) for the third quarter of 2014, compared with RMB20.9 million in the third

Selling expenses in the network business were RMB27.5 million ($4.5 million) for the third quarter of 2014, representing an increase of

11.4% from the third quarter of 2013. The increase was consistent with the higher revenue during the quarter.

General and administrative expenses in the

network business were RMB20.1 million ($3.3 million), compared with RMB13.3 million for the third quarter of 2013.The increase was primarily due to higher travel and meeting expenses. During the quarter, the Company collected RMB20 million

historical bad debts that were previously written off, resulting in net general and administrative expenses of RMB0.1 million for the quarter.

receivable from the network business was RMB258.1 million ($42.1 million) as of September 30, 2014, compared to RMB281.9 million as of June 30, 2014. The average period of sales outstanding for accounts receivable, or Days Sales

Outstanding (DSO), was 173 days for the third quarter of 2014, compared to 156 days for the second quarter of 2014.

As of September 30, 2014, the

Company, not including Chang an Hospital, had bank credit lines of RMB2,920.0 million ($448.3 million), of which RMB1,065.3 million ($173.6 million) was utilized, inclusive of the IFC loan of $50 million of which $20 million in convertible

loans was utilized since Feb 2014. The company is working with IFC for the disbursement of the remaining $30 million in A-Loan currently.

third quarter of 2014, the Company handled 7,700 patient treatment cases and 78,829 patient diagnostic cases in the center network, representing a 3.8% decrease and a 0.5% decrease from the third quarter of 2013, respectively.

Net revenues from the hospital business were RMB122.5 million ($20.0 million) for the third quarter of 2014, an increase of 19.0% from the third quarter of

2013. Net revenues from the hospital business for the third quarter of 2014 were comprised of:

Cost of service for the hospital business for the third quarter of 2014 was RMB106.5 million ($17.3 million), of which the medicine cost was RMB44.4 million

($7.2 million) and the medical service cost was RMB62.1 million ($10.1 million).

Gross profit margin of the hospital business was 13.1% for the third

quarter of 2014, as compared with 14.0% from the third quarter of 2013. Higher salary and compensation costs to the medical team were the main reasons for the decrease in gross profit margin.

Capital expenditure of the hospital business was RMB8.5 million ($1.4 million) for the third quarter of 2014, compared with RMB6.7 million for the third

General and administrative expenses in the hospital business were RMB4.7 million ($0.8 million) for the third quarter of 2014, compared

with RMB4.5 million for the third quarter of 2013.

As of September 30, 2014, Chang an Hospital had accounts receivable of RMB47.0 million ($7.7

million), compared to RMB43.9 million as of June 30, 2014. The number of day sales outstanding was 34 days, compared to 31 days for the second quarter of 2014. The accounts receivable balance was mainly related to medical revenues covered by

various government-sponsored insurance programs. Chang an Hospital settles the balance with the local social insurance bureau on a periodic basis.

Chang an Hospital received 160,181 outpatients and 8,505 inpatients for the third quarter of 2014. The average bed utilization for the quarter was 85.2%.

The average number of days of hospital stay was 8.8 days per patient for the quarter. Chang an Hospital operated 1,015 beds as of September 30, 2014.

Chang an Hospital is a leading private-owned for-profit general hospital, located in Xi an, Shanxi Province. Established in 2002, Chang an

Hospital had 57 departments with over 1,502 medical and non-medical staff as of September 30, 2014.

On October 27, 2014, the Company announced that it has received relevant government approvals to establish a free-standing radiotherapy cancer center,

Datong Meizhong Jiahe Cancer Center ( Datong Center ) in Datong City, Shanxi Province.

The Datong Center, a 100%-owned subsidiary of Concord Medical, will provide advanced, best-practice diagnostic

and radiotherapy services. The 100 bed- facility is completed, will be the first free-standing center in the Concord Medical network. Construction is expected to begin in November 2014 and the center will be operational in 2015.

The Datong center will be registered as a specialty cancer hospital with all required departments, including radiation, imaging, test laboratory, inpatient,

and nursing. This center will apply to join the local social insurance coverage. The Datong center represents an important step of the Company s broader strategy to build a nationwide chain of free-standing cancer treatment and diagnosis

centers in the future.

2014 fiscal year, the Company expects earnings in the range of $0.45 to $0.50 per ADS, or $20.3 million to $22.5 million in Net Income Attributable to Ordinary Shareholders. The Company forecasts construction will start on Datong Meizhong Jiahe

Cancer Center during 2014.

These estimates are based on current market and operating conditions, are subject to change, and may be impacted positively or

negatively by factors outside the Company s control, including but not limited to macroeconomic events in the markets in which the Company operates. See Safe Harbor Statement below for additional information regarding

forward-looking statements.

Conference Call Information

Medical s management will hold an earnings conference call at 8:00 a.m. Eastern Time on November 18, 2014 (9:00 p.m. Beijing/Hong Kong time on November 18, 2014).

Dial-in details for the earnings conference call are as follows:

A replay of the conference call may be accessed by phone at the following numbers for 7 days:

Additionally, a live and archived webcast of this conference call will be available at http://ir.concordmedical.com/.

About Concord Medical

Services Holdings Limited is an operator of specialty cancer hospitals and the largest network of radiotherapy and diagnostic imaging centers in China. As of September 30, 2014, the Company operated a network of 141 centers with 81 hospital

partners that spanned 56 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily

operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for

patients. For more information, please see http://ir.concordmedical.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended,

and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as anticipate, believe, estimate, expect,

forecast, intend, may, plan, project, predict, should and will and similar expressions. These forward looking statements are based upon management s

current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are by their nature, subject to a number of risks and uncertainties that could cause actual performance and

results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of

patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; technological or therapeutic changes

affecting the field of cancer treatment and diagnostic imaging; and possible effects on consumers and hospitals, hospital construction, and suppliers, as a result of inflation and the Chinese government s policies and actions to control

inflation. Further information regarding these and other risks is included in the Company s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The Company does not assume any obligation to update any

forward-looking statement, except as required by law.

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ( GAAP ),

Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense and changes in fair value of derivatives.

The Company believes excluding share-based compensation expense and changes in fair value of derivatives from its GAAP financial measures is useful for its management and investors to assess and analyze the Company s core operating results, as

such expense is not directly attributable to the underlying performance of the Company s business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation

expense and changes in fair value of derivatives are important in helping investors to understand the Company s current financial performance and future prospects and to compare business trends among different reporting periods on a consistent

basis. In addition, Concord Medical also presents the non-GAAP measure of Adjusted EBITDA, which is defined in this announcement as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses, changes in fair

value of derivatives and other adjustments. Other adjustments include foreign exchange gain (loss), loss from disposal of property, plant and equipment and other income or expense. Furthermore, Adjusted EBITDA eliminates the impact of items

that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance

and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to

GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

For more information, please contact:

Mr. Adam J. Sun (Chinese and English)